Cd4-IRES-DTRGFP

Nomenclature

C57BL/6Smoc-Cd4em5(IRES-DTREGFP)Smoc

Cat. NO.

NM-KI-190121

Strain State

Repository Live

Export PDF

Gene Summary

Gene Symbol
Cd4

Model Description

A IRES-DTREGFP expression cassette was knocked into the Cd4 gene stop codon site.

Validation Data

image.png

Fig.1 Expression analysis of CD4 and GFP on CD3+T in blood of CD4-IRES-DTRGFP mice.

Leukocytes were collected from the blood of 9-week-old CD4-IRES-DTRGFP mice, and analyzed by flow cytometry. Most CD4+T cells (97.3%) were GFP-positive cells.

验证数据-CD4-IRES-DTR-EGFP-图片2.png

Fig.2 CD4+ T cell and various immune cell populations in peripheral blood of CD4-IRES-DTR-EGFP mice. (In collaboration with CrownBio)

C57BL/6 mice and CD4-IRES-DTR-EGFP mice were simultaneously injected with diphtheria toxin. Results showed that after injection, CD4+ T cells and Treg cells in peripheral blood of CD4-IRES-DTR-EGFP mice were gradually depleted to 0%, while the proportion of CD8+ T cells in peripheral blood relatively increased. In contrast, immune cells such as B cells, NK cells, NKT cells, and DCs exhibited similar trends in peripheral blood between CD4-IRES-DTR-EGFP mice and wild-type mice.

验证数据-CD4-IRES-DTR-EGFP-图片3.png

Fig.3 Tumor growth in CD4-IRES-DTR-EGFP heterozygous MC38 tumor-bearing mice at different time points. (In collaboration with CrownBio)

After CD4-IRES-DTR-EGFP heterozygous mice and wild-type mice were inoculated with the MC38 colon cancer cell line, diphtheria toxin was injected on day 8 and subsequently administered every two days for a total of 3 doses. Tumor growth was monitored before and after treatment.


Publications 1piece


You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Workshop:Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more